Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio Growth (1y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | -347.04% |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | 73.00% |
| 10 | Alnylam Pharmaceuticals | 37.40 Bn | 34.39 Bn | 959.66 Mn | 1,378.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,378.45% |
| Dec 31, 2025 | 108,584.26% |
| Sep 30, 2025 | 470.48% |
| Jun 30, 2025 | -127.54% |
| Mar 31, 2025 | 121.28% |
| Dec 31, 2024 | 1.38% |
| Sep 30, 2024 | -132.32% |
| Jun 30, 2024 | 119.10% |
| Mar 31, 2024 | 76.19% |
| Dec 31, 2023 | -154.15% |
| Sep 30, 2023 | 210.22% |
| Jun 30, 2023 | -70.10% |
| Mar 31, 2023 | -49.37% |
| Dec 31, 2022 | 143.02% |
| Sep 30, 2022 | -39.23% |
| Jun 30, 2022 | -2.85% |
| Mar 31, 2022 | 39.53% |
| Dec 31, 2021 | 22.41% |
| Sep 30, 2021 | 42.45% |
| Jun 30, 2021 | 40.07% |